G-BA's Decision Not To Reimburse Plavix Will Stand

Germany's Federal Joint Committee on Healthcare (G-BA) has confirmed that it will not reimburse Plavix (clopidogrel) as a prophylactic treatment for cardiovascular disease. The decision comes as a result of findings by the Institute for Quality and Efficiency in Healthcare (IQWiG) in 2007 that Plavix had no real benefit over Aspirin when used as secondary

To read the full article, please choose one of the following options: